Delcath Systems (DCTH) 1.16 $DCTH Delcath Announces

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Delcath Systems (DCTH) 1.16 $DCTH

Delcath Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed Medical Journal
PR Newswire - Tue Mar 03, 7:00AM CST
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that the results from its Phase 3 clinical study, which completed enrollment in 2009, have been submitted for publication in a leading peer-reviewed medical journal. The clinical study utilized Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) for the treatment of melanoma patients with liver metastases.
DCTH: 1.16 (+0.02)

Delcath To Present At The 27th Annual Roth Conference
PR Newswire - Mon Mar 02, 7:30AM CST
Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that Company management will participate in the upcoming 27th Annual ROTH Conference being held from March 8-11, 2015 at the Ritz Carlton Laguna Niguel in Dana Point, Calif. Jennifer Simpson, PhD, MSN, CRNP, Delcath's interim President and Chief Executive Officer, will present a corporate overview and update on March 10, 2015 at 4:00 p.m. Pacific time.
DCTH: 1.16 (+0.02)

Delcath expects USD2.8m from public offering of common stock and warrants
M2 - Thu Feb 12, 4:56AM CST
Medical company Delcath Systems (NasdaqCM CTH) said on Wednesday that it has priced its public offering of 2,460,000 shares of its common stock and warrants.
DCTH: 1.16 (+0.02)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 11:45AM CST

JIVE: 5.01 (-0.02), JONE: 8.68 (+0.26), FXEN: 1.83 (-0.03), CDTI: 1.98 (-0.02), SGMO: 17.55 (-0.51), EVRY: 1.00 (unch), INXN: 29.87 (-0.21), RLOC: 2.98 (-0.02), ATEN: 4.33 (-0.11), BLDP: 2.29 (-0.06), PNTR: 8.85 (+0.06), PRSS: 3.48 (-0.02), BXE: 2.99 (-0.06), ANTH: 6.12 (+0.59), PIR: 11.96 (-0.09), PSTR: 3.58 (-0.17), MKTO: 26.56 (-0.42), ANDE: 42.11 (-3.25), DGLY: 12.81 (+0.43), DCTH: 1.16 (+0.02)

Delcath drops 24% on equity offering
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 9:22AM CST

DCTH: 1.16 (+0.02)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 8:13AM CST

FCEL: 1.41 (+0.09), ADXS: 11.90 (+0.80), JONE: 8.68 (+0.26), INXN: 29.87 (-0.21), SDRL: 10.55 (-0.39), NBG: 1.43 (-0.08), GNW: 7.67 (+0.06), WBAI: 14.50 (+0.70), PME: 2.52 (-0.03), RAD: 7.65 (-0.03), BLDP: 2.29 (-0.06), BXE: 2.99 (-0.06), PXD: 156.17 (-4.27), ACHN: 11.39 (+0.40), SDR: 4.55 (-0.01), LGF: 32.75 (-0.76), PIR: 11.96 (-0.09), AOL: 40.80 (+0.25), GNRC: 49.14 (-0.56), GOL: 2.99 (-0.12), DCTH: 1.16 (+0.02), CHS: 17.50 (-0.23)

Delcath Prices $2.8 Million Public Offering of Common Stock and Warrants
PR Newswire - Wed Feb 11, 7:33AM CST
Delcath Systems, Inc. (NASDAQ: DCTH) today announced that it has priced an underwritten public offering of 2,460,000 shares of its common stock and warrants to purchase up to 1,107,000 shares of common stock at a combined price to the public of $1.15 per share and related warrant for gross proceeds of $2.8 million. The warrants are exercisable beginning on the date six months after the date of issuance at an exercise price of $1.38 per share and will expire, unless exercised, on the fifth anniversary of the date of issuance. The net proceeds from the sale of the shares and the related warrants, after deducting the underwriters' discounts and other estimated offering expenses payable by Delcath, will be approximately $2.4 million, which does not include any potential proceeds from the cash exercise of any warrants.
DCTH: 1.16 (+0.02)

Delcath to launch public offering of common stock and warrants
M2 - Wed Feb 11, 4:37AM CST
Medical device company Delcath Systems (NasdaqCM CTH) said on Tuesday that it intends to issue shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.
DCTH: 1.16 (+0.02)

Delcath Announces Proposed Public Offering Of Common Stock And Warrants
PR Newswire - Tue Feb 10, 3:05PM CST
Delcath Systems, Inc. (NASDAQ: DCTH) today announced its intention to offer, subject to market and other conditions, shares of its common stock and warrants to purchase shares of common stock in an underwritten public offering. The proceeds from the offering (including any resulting from the exercise of the warrants, if any) will primarily be used for general corporate purposes, including, but not limited to, funding of clinical trials, commercialization of products, obtaining regulatory approvals, research, capital expenditures and working capital.
DCTH: 1.16 (+0.02)

DELCATH RECEIVES VALUE 4 REIMBUREMENT STATUS FOR CHEMOSAT IN GERMANY
Thomson Reuters ONE - Tue Feb 03, 6:01AM CST
NEW YORK (February 3, 2015) - Delcath Systems, Inc. (NASDAQ: DCTH) announces that the Institut fur das Entgeltsystem im Krankenhaus (InEk), the German federal reimbursement agency, has affirmed Value 4 coverage status for 2015 for the treatment of patients with liver metastases with the Delcath Hepatic CHEMOSAT(R) Delivery System.
DCTH: 1.16 (+0.02)

Earnings Preview: Intuitive Surgical Q4 2014
Selerity Research - at Seeking Alpha - Fri Jan 16, 12:49PM CST

ISRG: 494.04 (-5.48), RTIX: 5.32 (-0.03), MDT: 76.48 (-2.02), ARAY: 8.64 (-0.21), PVG: 5.41 (-0.22), DCTH: 1.16 (+0.02)

OTC Daily Alert Stock Watch - Delcath Systems, Inc. (NASDAQ: DCTH)
WorldStockWire - Mon Dec 29, 3:00PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
DCTH: 1.16 (+0.02)

Metastatic Melanoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pb9ww/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Vical Incorporated - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Genentech, Inc. - MedImmune, LLC - Plexxikon Inc. - Delcath Systems, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Bayer AG - Incyte Corporation - Luitpold Pharmaceuticals, Inc. - Merck KGaA - Celldex Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - AVAX Technologies, Inc. - Oncolytics Biotech Inc. - Antisoma plc - Progen Pharmaceuticals Limited - HanAll Biopharma Co., Ltd. - Provectus Biopharmaceuticals, Inc. - BioAlliance Pharma SA For more information visit http://www.researchandmarkets.com/research/2pb9ww/metastatic
ONCY: 0.90 (-0.15), PFE: 33.97 (-0.50), INCY: 90.00 (-1.97), CLDX: 29.39 (-0.39), AMGN: 154.88 (-4.72), BMY: 65.12 (-0.93), GSK: 46.73 (-0.87), MNTA: 14.57 (-0.10), PVCT: 0.83 (-0.02), VICL: 0.99 (-0.04), AZN: 66.27 (-1.91), DCTH: 1.16 (+0.02), NVS: 97.46 (-1.49), CELGZ: 3.21 (unch)

DELCATH STRENGTHENS BOARD OF DIRECTORS WITH NEW APPOINTMENTS
Thomson Reuters ONE - Mon Dec 15, 6:01AM CST
Industry Veterans Add Clinical Trial, Financial, and Drug Development Expertise
DCTH: 1.16 (+0.02)

Delcath Systems adds Hannover Medical School Hospital and Jena University Hospital to its Global Phase 2 HCC Programme
M2 - Fri Dec 12, 7:01AM CST
Medical device company Delcath Systems (NasdaqCM CTH) disclosed on Thursday the addition of two research hospitals in Germany to its Global Phase 2 Clinical Programme for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC), or primary liver cancer.
DCTH: 1.16 (+0.02)

DELCATH ADDS NEW CENTERS TO GLOBAL PHASE 2 HCC PROGRAM
Thomson Reuters ONE - Thu Dec 11, 6:01AM CST
Hannover Medical School Hospital and Jena University Hospital in Germany Open for Enrollment
DCTH: 1.16 (+0.02)

Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 4.17 (-0.12), AMGN: 154.88 (-4.72), RGLS: 20.70 (-0.43), LLY: 68.41 (-2.18), GSK: 46.73 (-0.87), PVCT: 0.83 (-0.02), CANF: 4.49 (+0.02), DCTH: 1.16 (+0.02), NVS: 97.46 (-1.49), XLRN: 40.55 (-0.79)

DELCATH ANNOUNCES TREATMENT OF FIRST PATIENT IN PHASE 2 TRIAL OF MELPHALAN HEPATIC DELIVERY SYSTEM IN PRIMARY LIVER CANCER
Thomson Reuters ONE - Mon Nov 10, 5:31AM CST
Goethe University Hospital Frankfurt Performs First Treatment
DCTH: 1.16 (+0.02)

Delcath's (DCTH) CEO Dr. Jennifer Simpson on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 5:58PM CST

DCTH: 1.16 (+0.02)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 78

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 49

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 139

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 83

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 77

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 93

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 63

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Dawson Struggles With Q3 Losses Despite Growth Prospects

Updated Category News Views 110

Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 69

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading
China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 135

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading

Top 5 Most Recently Viewed Articles

Air Products Secures $140 Million in NASA Liquid Hydrogen Contracts

Updated Category News Views 85

Air Products Receives Significant NASA Contracts Air Products, a leading supplier in the industrial gases market, recently announced an impressive contract award from NASA valued at over $140 million. This contract aims at supplying liquid hydrogen for various NASA facilities, most notably the renowned Kennedy Space Center and other significant sites where vital space...

Continue Reading
Navigating Market Realities: A Look Ahead for Investors

Updated Category News Views 158

The Uncomfortable Truth About Market Valuations Many investors may feel uneasy hearing this, but it’s essential to face the real data regarding market potential. After analyzing the last 40 years of market information from various developed economies, including movements in China, the reality might deter those banking on robust returns in the forthcoming decade. There's...

Continue Reading
Sodexo Unveils Its Universal Registration Document for 2025

Updated Category News Views 367

Introduction to Sodexo's Fiscal 2025 Document Sodexo has made significant strides in enhancing transparency and providing essential information through its recently filed Fiscal 2025 Universal Registration Document (URD). This document, which is now accessible to investors and stakeholders, showcases the company's ongoing commitment to accountability and sustainability....

Continue Reading
Paratus Energy's Q4 2025 Results: Key Indicators to Analyze

Updated Category News Views 197

Paratus Energy Services Ltd. (PLSV) is about to drop its unaudited interim Q4 2025 financial results on February 27, 2026. But here’s the kicker—traders are left with scant intel leading into this call, and that can rattle markets. First off, let’s talk about the earnings whispers. The usual playbook includes scouring through EPS projections and revenue figures, but...

Continue Reading
Keefe Adjusts Rating for Bank of N.T. Butterfield Amid Challenges

Updated Category News Views 72

Keefe Downgrades the Bank of N.T. Butterfield Stock Rating Recently, Keefe, Bruyette & Woods revised its recommendation for Bank of N.T. Butterfield (NYSE: NTB) stock, shifting the rating from Outperform to Market Perform. The price target has also been adjusted from $44 to $41. This reflects the bank's forecast of significant net interest income (NII) challenges...

Continue Reading